Drug Database · Clinicians

Dexamethasone + Neomycin + Polymyxin b

Brands (29) Syntemax, Maxitrol, Vistacom…Show all

Corticosteroid (Corticosteroid Hormone Receptor Agonists) US FDA class
Antibacterial/Corticosteroid/Antifungal; Corticosteroid anti-infectives combination; and others PH FDA category
Fixed-dose combination.

Rx · Prescription drug37 PH products
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
Label text on this page: US FDA-approved label via DailyMed/openFDA, set ID ecfb954f-5554-0ad2-e053-2995a90a7516, version date October 24, 2025 (Maxitrol · Harrow Eye, LLC). Reproduced verbatim. Philippine-approved indications and doses may differ: check the PH package insert.

Use: Labeled indications

  • INDICATIONS AND USAGE For steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial infection exists.
US FDA label
Full indications and usage US FDA label

INDICATIONS AND USAGE For steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial infection exists. Ocular corticosteroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of corticosteroids use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation.

They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns; or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye.

The particular anti-infective drug in this product is active against the following common bacterial eye pathogens: Staphylococcus aureus, Escherichia coli, Haemophilus influenzae, Klebsiella /Enterobacter species, Neisseria species, and Pseudomonas aeruginosa. This product does not provide adequate coverage against: Serratia marcescens and S treptococci, including Streptococcus pneumoniae.

Contraindications

CONTRAINDICATIONS MAXITROL ® (neomycin and polymyxin B sulfates and dexamethasone ophthalmic suspension) is contraindicated in most viral diseases of the cornea and conjunctiva, including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella, and also in mycobacterial infection of the eye and fungal diseases of ocular structures. MAXITROL is also contraindicated in individuals with known or suspected hypersensitivity to any of the ingredients of this preparation and to other corticosteroids.

US FDA label

Dosing: Adult

Dosage and administration (US label) US FDA label

DOSAGE AND ADMINISTRATION One to two drops in the conjunctival sac(s). In severe disease, drops may be used hourly, being tapered to discontinuation as the inflammation subsides. In mild disease, drops may be used up to four to six times daily. Not more than 20 mL should be prescribed initially, and the prescription should not be refilled without further evaluation as outlined in PRECAUTIONS above.

Dosing: Altered kidney function

No kidney-specific text is available from the US label for this generic yet. Check the Philippine package insert in the products table.

Kidney-specific guidance from renalcarematters.com: in preparation.

Dosing: Pediatric

Pediatric use (US label) US FDA label

Pediatric Use Safety and effectiveness in pediatric patients below the age of 2 years have not been established.

Dosing: Older adult

Geriatric use (US label) US FDA label

Geriatric Use No overall differences in safety or effectiveness have been observed between elderly and younger patients.

Dosage forms

Philippines

  • Otic solution: 1 mg/3.5 mg/10,000 IU per mL, 5 mg/1 mg/10,000 Units per mL, 10,000 units/5 mg/1 mg per mL
  • Ophthalmic & otic suspension: 1 mg/3. 5 mg/6000 IU, 1 mg/3.5 mg/6000 IU
  • Ophthalmic suspension: 1 mg/3.5 mg/6,000 IU per mL, 10,000 units/3.5 mg/1 mg per mL
  • Sterile ophthalmic solution: 6,000 Units/5 mg/1 mg
  • Sterile ophthalmic suspension: 1 mg/3,500 IU/6,000 IU per mL, 8,000 units/3.5 mg/1 mg per mL
  • Ophthalmic & otic solution: 1 mg/3.5 mg/6000 IU
  • Ophthalmic ointment: 10,000 units/3.5 mg/1 mg per g
  • Ophthalmic solution: 1 mg/3.5 mg/10,000 IU per mL
  • Ophthalmic/otic suspension: 1.25 mg/3.5 mg/1 mg per mL
  • Opthalmic suspension: 1 mg/3.5 mg/6,000 IU per mL

and 3 more forms; see the products table.

Registered products in the Philippines

37 products registered with the Food and Drug Administration (FDA) Philippines list Dexamethasone + Neomycin + Polymyxin b as the generic name (including products registered under a variant spelling). Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Also registered under: Dexamethasone + Neomycin (as sulfate) + Polymyxin-B-Sulfate (11 products) · POLYMYXIN B SULFATE NEOMYCIN SULFATE DEXAMETHASONE (1 product). Products registered under these spellings are included in the table and marked.

Verify on PH FDA portal

All registered products37
Philippine FDA-registered products for Dexamethasone + Neomycin + Polymyxin b
Package insert
Dexa-NPDexamethasone + Neomycin (as sulfate) + Polymyxin-B-SulfateVariant spelling
1 mg/ 3.5 mg/6000 IU Ophthalmic & Otic SuspensionBox of 1 LDPE Plastic Bottle x 5 mL with HDPE Tamper Proof Cap
Rx
Egyptian International Pharmaceutical Industries Co.Egypt
Preventia Healthcare Inc.Importer: Ambica International Corporation
DRP-7734-07
Mar 16, 2028
DexatrolDexamethasone + Neomycin (as sulfate) + Polymyxin-B-SulfateVariant spelling
1 mg/3.5 mg/6000 I.U Ophthalmic SuspensionBox of 1 LDPE plastic bottle x 5 mL with HDPE tamper proof cap
Rx
Egyptian International Pharmaceutical Industries Co.Egypt
Pharmabiz Solutions, Inc.Importer: Ambica International Corporation
DRP-7734
Mar 16, 2028
DexneomyxDexamethasone + Neomycin (as sulfate) + Polymyxin-B-SulfateVariant spelling
1 mg/3. 5 mg/6000 IU Ophthalmic & Otic SuspensionLDPE Plastic Bottle x 5 mL with HDPE Tamper Proof Cap (Box of 1's)
Rx
Egyptian International Pharmaceutical Industries Co.Egypt
Ambitech Biopharmaceuticals Inc.Importer: Ambica International Corporation
DRP-7734-12
Mar 16, 2028
DuodexDexamethasone + Neomycin (as sulfate) + Polymyxin-B-SulfateVariant spelling
1 mg /3. 5 mg /6000 IU Ophthalmic & Otic SuspensionBox of 1 LDPE Plastic Bottle x 5 mL with HDPE Tamper Proof Cap
Rx
Egyptian International Pharmaceutical Industries Co.Egypt
Sensorycare Pharma Co.Importer: Ambica International Corporation
DRP-7734-13
Mar 16, 2028
GoxetrolDexamethasone + Neomycin (as sulfate) + Polymyxin-B-SulfateVariant spelling
1 mg/3.5 mg/6000 I.U. Ophthalmic & Otic SuspensionBox of 1 LDPE Plastic Bottle x 5 mL with HDPE Tamper Proof Cap
Rx
Egyptian International Pharmaceutical Industries Co.Egypt
Applied Pharmaceutical Distribution IncImporter: Ambica International Corporation
DRP-7734-05
Mar 16, 2028
IconPolymyxin B (as Sulfate) + Neomycin (as Sulfate) + Dexamethasone (as Sodium Phosphate)
6,000 Units/ 5 mg/ 1 mg Sterile Ophthalmic Solution (Drops)White Plastic Dropper-Tipped Bottle x 5 mL (Box of 1's)
Rx
Ashford Pharmaceutical Laboratories, Inc.Philippines
Pharmabiz Solutions, Inc.Trader: Medlife Pharma, Inc.
DRP-442-05
Aug 14, 2031
IcumaxDexamethasone + Neomycin (as Sulfate) + Polymyxin-B Sulfate
1 mg / 3.5 mg / 6000 I.U. Ophthalmic and Otic SuspensionLDPE Plastic Bottle x 5 mL with HDPE Tamper Proof Cap (Box of 1's)
Rx
Egyptian International Pharmaceutical Industries Co.Egypt
All-Bio Pharma, Inc.Importer: Ambica International Corporation
DRP-7734-02
Mar 16, 2028
IpodexDexamethasone + Neomycin (as Sulfate) + Polymyxin-B-SulfateVariant spelling
1 mg/ 3.5 mg / 6000 I.U. Ophthalmic and Otic SuspensionBox of 1 LDPE Plastic Bottle x 5 mL with HDPE Tamper Proof Cap
Rx
Egyptian International Pharmaceutical Industries Co. (EIPICO)Egypt
I-Senz Medical Inc.Importer: Ambica International Corporation
DRP-7734-03
Mar 16, 2028
IrodexPolymyxin B Sulfate + Neomycin Sulfate + Dexamethasone (as Sodium Phosphate)
10,000 units/5 mg/1 mg per mL Otic SolutionWhite Plastic Dropper-Tipped Bottle x 5 mL (Box of 1's)
Rx
Ashford Pharmaceutical Laboratories, Inc.Philippines
JNJ Pharma EnterprisesTrader: Medilife Pharma, Inc.
DRP-864-01
Jan 31, 2028
ISOREPolymyxin B (as Sulfate) + Neomycin (as Sulfate) + Dexamethasone (as Sodium Phosphate)
6,000 Units/ 5 mg/ 1mg Sterile Ophthalmic SolutionWhite Plastic Dropper-Tipped Bottle x 5 mL (Box of 1's)
Rx
Ashford Pharmaceutical Laboratories, Inc.Philippines
Trader: Medilife Pharma, Inc.
DRP-442
Aug 14, 2031
MaxidinDexamethasone + Neomycin (as Sulfate) + Polymyxin B Sulfate
1 mg/ 3.5 mg/ 6000 I.U. Ophthalmic & Otic SuspensionBox of 1 LDPE Plastic Bottle x 5 mL with HDPE Tamper proof cap
Rx
Egyptian International Pharmaceutical Industries Co. (EIPICO)Egypt
Medchoice Vision Care Inc.Importer: Ambica International Corporation
DRP-7734-01
Mar 16, 2028
MaxirapPolymyxin B Sulfate + Neomycin Sulfate + Dexamethasone
1.25 mg/ 3.5 mg/ 1 mg per mL Ophthalmic/Otic Suspension (Drops)5 mL net content in 10 mL white LDPE plastic bottle with LDPE nozzle and white LDPE cap Box of 1's
Rx
EL LABORATORIES, INC.Philippines
Trader: SENSOMED PHILS., INC.
DR-XY12845
Feb 6, 2029
MaxitrolDexamethasone + Neomycin Sulfate (equivalent to Neomycin) + Polymyxin B Sulfate
1 mg/3,500 IU/6,000 IU per mL Sterile Ophthalmic Suspension (Drops)Alcon LDPE (low density polyethylene) droptainer x 5 mL (Box of 1's)
Rx
Novartis Manufacturing NVBelgium
Importer: Novartis Healthcare Philippines, Inc.
DR-XY13465
Jun 27, 2031
MaxitrolDexamethasone + Polymyxin B Sulfate + Neomycin Sulfate
1 mg/6,000 IU/3,500 IU per gram Sterile Ophthalmic OintmentAluminum collapsible tube x 3.5 g Box of 1’s
Rx
Alcon-Couvreur NVBelgium
Importer: Novartis Healthcare Philippines, Inc.
DR-XY7883
Jul 1, 2029
NeladexDexamethasone + Neomycin (as sulfate) + Polymyxin B Sulfate
1 mg/3.5 mg/6,000 IU per mL Ophthalmic Suspension (Eye Drops)White Opaque LDPE Bottle with White LDPE Dropper and White HDPE-LDPE Cap x 5 mL (Box of 1's)
Rx
World Medicine Ilac Sanayi ve Ticaret A.S.Turkey
Bellus Life Solutions, Inc.
DRP-13774
Apr 17, 2028
Neodex-VPolymyxin B (as sulfate) + Neomycin (as sulfate) + Dexamethasone
10,000 units/3.5 mg/1 mg per mL Otic Suspension (Ear Drops)5 mL net volume in 10 mL capacity white LDPE dropper-tipped bottle with white LDPE nozzle and white HDPE cap
Rx
EL Laboratories, Inc.Philippines
Trader: Vista Pharma, Inc.
DR-XY27464
Sep 12, 2027
NeosporexDexamethasone + Neomycin (as sulfate) + Polymyxin-B-SulfateVariant spelling
1 mg/3.5 mg/6000 IU Ophthalmic & Otic SuspensionBox of 1 LDPE Plastic Bottle x 5 mL with HDPE Tamper Proof Cap
Rx
Egyptian International Pharmaceutical Industries Co.Egypt
Ophtha Pharma Traders Inc.Importer: Ambica International Corporation
DRP-7734-06
Mar 16, 2028
NeoticPolymyxin B Sulfate + Neomycin Sulfate + Dexamethasone (as Sodium Phosphate)
10,000 units/5 mg/1 mg per mL Otic SolutionWhite Plastic Dropper-Tipped Bottle x 5 mL (Box of 1's)
Rx
Ashford Pharmaceutical Laboratories, Inc.Philippines
All-Bio Pharma, Inc.Trader: Medilife Pharma, Inc.
DR-864-02
Jan 31, 2028
NoneDexamethasone + Neomycin (as sulfate) + Polymyxin B sulfate
1 mg / 3.5 mg/ 6,000 IU per mL Opthalmic Suspension (Eye Drops)White Opaque LDPE Bottle with White LDPE Dropper and White HDPE-LDPE Cap x 5 mL (Box of 1's)
Rx
World Medicine Ilac Sanayi ve Ticaret A.S.Turkey
Ritemed Phils., Inc.Importer: Bellus Life Solutions, Inc.
DRP-13774-01
Apr 17, 2028
NonePolymyxin B Sulfate + Neomycin Sulfate + Dexamethasone
8,000 units/ 3.5 mg/ 1 mg per mL Sterile Ophthalmic Suspension (Eye Drops)10 mL White LDPE Plastic Bottle with Plug and Cap x 7.5 mL (net content) (Box of 1's)
Rx
E.L. Laboratories, Inc.Philippines
Trader: Celsus Pharmaceuticals Phils., Inc.
DR-XY28137
Feb 24, 2029
OtixinNeomycin Sulfate + Dexamethasone Sodium Phosphate + Polymyxin B Sulfate
5 mg/ 1 mg/ 10,000 Units per mL Otic Solution (Drops)LDPE Plastic Bottle with Cap x 5 mL (Box of 1's)
Rx
Ashford Pharmaceutical Laboratories Inc.Philippines
Trader: Vendiz Pharmaceuticals, Inc.
DRP-11255
Oct 24, 2028
PND-CarePolymyxin B Sulfate + Neomycin Sulfate + Dexamethasone (as Sodium Phosphate)
10,000 units/5 mg/1 mg per mL Otic SolutionWhite Plastic Dropper-Tipped Bottle x 5 mL (Box of 1's)
Rx
Ashford Pharmaceutical Laboratories, Inc.Philippines
Sensorycare Pharma Co.Trader: Medilife Pharma, Inc.
DRP-864-06
Jan 31, 2028
Polymix-DDexamethasone + Neomycin (as sulfate) + Polymyxin-B-SulfateVariant spelling
1 mg / 3.5 mg / 6000 IU Ophthalmic & Otic SuspensionBox of 1 LDPE Plastic Bottle x 5 mL with HDPE Tamper Proof Cap
Rx
Egyptian International Pharmaceutical Industries Co.,Egypt
Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation
DRP-7734-10
Mar 16, 2028
PonedaDexamethasone + Neomycin (as sulfate) + Polymyxin-B-SulfateVariant spelling
1 mg / 3.5mg/6000 IU Ophthalmic & Otic SolutionLDPE Plastic Bottle x 5 mL with HDPE Tamper Proof Cap (Box of 1's)
Rx
Egyptian International Pharmaceutical Industries Co. (EIPICO)Egypt
AGB Pharmaceutical Trading and Consultancy CorporationImporter: Ambica International Corporation
DRP-7734-08
Mar 16, 2028
PonedexPolymyxin B Sulfate + Neomycin Sulfate + Dexamethasone (as Sodium Phosphate)
10,000 Units / 5 mg/ 1 mg per mL Otic SolutionWhite Plastic Dropper-Tipped Bottle x 5 mL (Box of 1's)
Rx
Ashford Pharmaceutical Laboratories, Inc.Philippines
Celsus Pharmaceuticals Phils., Inc.Trader: Medilife Pharma, Inc.
DRP-864-07
Jan 31, 2028
RapidaxPolymyxin B Sulfate + Neomycin Sulfate + Dexamethasone (as Sodium Phosphate)
10,000 units/5 mg/1 mg per mL Otic SolutionWhite Plastic Dropper-Tipped Bottle x 5 mL (Box of 1's)
Rx
Ashford Pharmaceutical Laboratories, Inc.Philippines
Trader: Medilife Pharma, Inc.
DRP-864
Jan 31, 2028
RaypondexDexamethasone + Neomycin (as sulfate) + Polymyxin-B-SulfateVariant spelling
1 mg / 3.5 mg/ 6000 IU Ophthalmic & Otic SuspensionBox of 1 LDPE Plastic Bottle x 5 mL with HDPE Tamper Proof Cap
Rx
Egyptian International Pharmaceutical Industries Co.Egypt
RCL Ophthalmic SurgicalsImporter: Ambica International Corporation
DRP-7734-09
Mar 16, 2028
RetapidecxDexamethasone + Neomycin (as sulfate) + Polymyxin-B-SulfateVariant spelling
1 mg/ 3.5 mg/ 6000 IU Ophthalmic & Otic SuspensionBox of 1 LDPE Plastic Bottle x 5 mL with HDPE Tamper Proof Cap
Rx
Egyptian International Pharmaceutical Industries Co.Egypt
Reta DrugImporter: Ambica International Corporation
DRP-7734-11
Mar 16, 2028
SyntemaxDexamethasone sodium phosphate/ Neomycin (as sulfate) / Polymyxin B (as sulfate)
1 mg / 3.5 mg / 10,000 IU per mL Ophthalmic Solution (Drops)5ml LDPE squeezable plastic bottle (Box of 1's)
Rx
Ashford Pharmaceutical Laboratories, Inc.Philippines
Trader: Optaderm Pharma Inc.
DRP-15128
Jun 25, 2027
SyntemaxDexamethasone sodium phosphate/ Neomycin (as sulfate)/ Polymyxin B (as sulfate)
1 mg / 3.5 mg / 10,000 IU per mL Otic Solution (Drops)5 mL LDPE squeezable bottle (Box of 1's)
Rx
Ashford Pharmaceutical Laboratories, Inc.Philippines
Trader: Optaderm Pharma Inc.
DRP-15127
Jun 25, 2027
SyntemaxDexamethasone sodium phosphate/ Neomycin (as sulfate)/ Polymyxin B (as sulfate)
1mg/3.5mg/10,000 I.U. per mL Ophthalmic Solution (Drops)5mL LDPE squeezable plastic bottle (Box of 1's)
Rx
Ashford Pharmaceuticals Laboratories, Inc.Philippines
Trader: Optaderm Pharma Inc.
DR-X7343
Jun 25, 2027
SyntemaxDexamethasone sodium phosphate/Neomycin (as sulfate)/Polymyxin B (as sulfate)
1mg/3.5mg/10,000 I.U. per mL Otic Solution (Drops)5mL LDPE squeezable bottle (Box of 1's)
Rx
Ashford Pharmaceutical Laboratories, Inc.Philippines
Trader: Optaderm Pharma Inc.
DR-XY25083
Jun 25, 2027
TricombPolymyxin B Sulfate + Neomycin Sulfate + Dexamethasone (as Sodium Phosphate)
10,000 units/5 mg/1 mg per mL Otic SolutionWhite Plastic Dropper-tipped Bottle x 5 mL (Box of 1's)
Rx
Ashford Pharmaceutical Laboratories, Inc.Philippines
Pharmabiz Solutions, Inc.Trader: Medilife Pharma, Inc.
DRP-864-04
Jan 31, 2028
TriloupePolymyxin B Sulfate + Neomycin Sulfate + Dexamethasone (as Sodium Phosphate)
10,000 units/5 mg/1 mg per mL Otic SolutionWhite Plastic Dropper-Tipped Bottle x 5 mL Box of 1's
Rx
Ashford Pharmaceutical Laboratories, Inc.Philippines
PNJ Pharma EnterpriseTrader: Medilife Pharma, Inc.
DRP-864-05
Jan 31, 2028
UnbrandedPOLYMYXIN B SULFATE NEOMYCIN SULFATE DEXAMETHASONEVariant spelling
8,000 units/3.5mg/1mg per mL Sterile Otic Suspension (Ear Drops)10mL White LDPE Plastic Bottle with Plug and Cap x 7.5mL [net content] (Box of 1's)
Rx
e.L Laboratories, Inc.Philippines
Trader: CELSUS PHARMACEUTICALS PHILS., INC.
DR-XY28136
Feb 24, 2029
VistacomPolymyxin B (as sulfate) + Neomycin (as sulfate) + Dexamethasone
10,000 units / 3.5 mg / 1 mg per mL Ophthalmic Suspension (Drops)5 mL (net content) in 10 mL HDPE pilfer-guard eye dropper plastic bottle in a box
Rx
EL Laboratories, Inc.Philippines
Trader: Vista Pharma, Inc.
DR-XY27507
May 8, 2027
VistacomPolymyxin B (as sulfate) + Neomycin (as sulfate) + Dexamethasone
10,000 units/3.5 mg/1 mg per g Ophthalmic OintmentAluminum collapsible tube x 3.5 g (Box of 1's)
Rx
Ashford Pharmaceutical Laboratories, Inc.Philippines
Trader: Vista Pharma, Inc.
DR-XY28440
Sep 11, 2027

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

Warnings/Precautions

Warnings and precautions (US label) US FDA label

WARNINGS NOT FOR INJECTION. Use of ocular steroids may prolong the course and may exacerbate the severity of many viral infections of the eye (including herpes simplex). Employment of a corticosteroid medication in the treatment of patients with a history of herpes simplex requires great caution; frequent slit lamp microscopy is recommended.

Prolonged use of corticosteroids may result in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision, and in posterior subcapsular cataract formation. Prolonged use may also suppress the host immune response and thus increase the hazard of secondary ocular infections. Acute purulent or parasitic infections of the eye may be masked or activity enhanced by the presence of corticosteroid medication.

Various ocular diseases and long-term use of topical corticosteroids have been known to cause corneal and scleral thinning. Use of topical corticosteroids in the presence of thin corneal or scleral tissue may lead to perforation. If this product is used for 10 days or longer, intraocular pressure (IOP) should be routinely monitored even though it may be difficult in children and uncooperative patients.

Steroids should be used with caution in the presence of glaucoma. IOP should be checked frequently. The use of steroids after cataract surgery may delay healing and increase the incidence of bleb formation. MAXITROL ® (neomycin and polymyxin B sulfates and dexamethasone ophthalmic suspension) is not for injection. It should never be injected subconjunctivally, nor should it be directly introduced into the anterior chamber of the eye.

Products containing neomycin sulfate may cause cutaneous sensitization. Sensitivity to topically administered aminoglycosides, such as neomycin, may occur in some patients. Severity of hypersensitivity reactions may vary from local effects to generalized reactions such as erythema, itching, urticaria, skin rash, anaphylaxis, anaphylactoid reactions, or bullous reactions.

If hypersensitivity develops during use of the product, treatment should be discontinued. Cross-hypersensitivity to other aminoglycosides can occur, and the possibility that patients who become sensitized to topical neomycin may also be sensitive to other topical and/or systemic aminoglycosides should be considered.

Adverse reactions

Adverse reactions (US label) US FDA label

ADVERSE REACTIONS Adverse reactions have occurred with corticosteroid/anti-infective combination drugs which can be attributed to the corticosteroid component, the anti-infective component, or the combination. Exact incidence figures are not available since no denominator of treated patients is available. Reactions occurring most often from the presence of the anti-infective ingredient are allergic sensitizations.

The reactions due to the corticosteroid component are: elevation of IOP with possible development of glaucoma, and infrequent optic nerve damage; posterior subcapsular cataract formation; and delayed wound healing. Corticosteroid-containing preparations have also been reported to cause perforation of the globe. Keratitis, conjunctivitis, corneal ulcers, and conjunctival hyperemia have occasionally been reported following use of steroids.

Additional adverse reactions identified from post marketing use include ulcerative keratitis, headache, and Stevens-Johnson syndrome. The following additional adverse reactions have been reported with dexamethasone use: Cushing’s syndrome and adrenal suppression may occur after use of dexamethasone in excess of the listed dosing instructions in predisposed patients, including children and patients treated with CYP3A4 inhibitors.

Pregnancy considerations

Pregnancy (US label) US FDA label

Pregnancy Dexamethasone has been shown to be teratogenic in mice and rabbits following topical ophthalmic application in multiples of the therapeutic dose. In the mouse, corticosteroids produce fetal resorptions and a specific abnormality, cleft palate. In the rabbit, corticosteroids have produced fetal resorptions and multiple abnormalities involving the head, ears, limbs, palate, etc.

There are no adequate or well-controlled studies in pregnant women. However, prolonged or repeated corticoid use during pregnancy has been associated with an increased risk of intra-uterine growth retardation. MAXITROL ® (neomycin and polymyxin B sulfates and dexamethasone ophthalmic suspension) should be used during pregnancy only if the potential benefit to the mother justifies the potential risk to the embryo or fetus.

Infants born of mothers who have received substantial doses of corticosteroids during pregnancy should be observed carefully for signs of hypoadrenalism.

Breastfeeding considerations

Lactation (US label) US FDA label

Nursing Mothers Systemically administered corticosteroids appear in human milk, could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects. It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in human milk. Because many drugs are excreted in human milk, caution should be exercised when MAXITROL ® (neomycin and polymyxin B sulfates and dexamethasone ophthalmic suspension) is administered to a nursing woman.

Pharmacokinetics

Pharmacokinetics (US label) US FDA label

CLINICAL PHARMACOLOGY Corticosteroids suppress the inflammatory response to a variety of agents and they probably delay or slow healing. Since corticosteroids may inhibit the body's defense mechanism against infection, a concomitant antimicrobial drug may be used when this inhibition is considered to be clinically significant in a particular case.

When a decision to administer both a corticosteroid and an antimicrobial is made, the administration of such drugs in combination has the advantage of greater patient compliance and convenience, with the added assurance that the appropriate dosage of both drugs is administered, plus assured compatibility of ingredients when both types of drugs are in the same formulation and, particularly, that the correct volume of drug is delivered and retained. The relative potency of corticosteroids depends on the molecular structure, concentration and release from the vehicle.

Formulary and pricing (Philippines)

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. U.S. Food and Drug Administration. Maxitrol · Harrow Eye, LLC [US FDA-approved label, version 5, October 24, 2025]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ecfb954f-5554-0ad2-e053-2995a90a7516
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph

This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .